<?xml version='1.0' encoding='utf-8'?>
<document id="18443793"><sentence text="A Bayesian population PK-PD model for ispinesib/docetaxel combination-induced myelosuppression."><entity charOffset="48-57" id="DDI-PubMed.18443793.s1.e0" text="docetaxel" /></sentence><sentence text="Ispinesib, a kinesin spindle protein inhibitor, blocks assembly of a functional mitotic spindle, leading to G2/M arrest"><entity charOffset="0-9" id="DDI-PubMed.18443793.s2.e0" text="Ispinesib" /></sentence><sentence text=" Docetaxel promotes tubulin assembly into microtubules while inhibiting microtubule de-polymerization leading to mitotic arrest"><entity charOffset="1-10" id="DDI-PubMed.18443793.s3.e0" text="Docetaxel" /></sentence><sentence text=" Prolonged (&gt; or =5 days) Gr 4 neutropenia and/or febrile neutropenia were the observed dose-limiting toxicities with both agents" /><sentence text=" Both agents are substrates and inhibitors of CYP3A4; thus, the potential for a drug-drug interaction exists" /><sentence text=" The goal was to fit a Bayesian population PK/PD model to characterize the relationship between the ispinesib/docetaxel combination and absolute neutrophil counts (ANC)"><entity charOffset="110-119" id="DDI-PubMed.18443793.s6.e0" text="docetaxel" /></sentence><sentence text="" /><sentence text="Escalating doses of docetaxel (60-75 mg/m(2)) were administered over 1 h followed by a 1-h infusion of escalating doses of ispinesib (8-12 mg/m(2)) on a 21-day schedule"><entity charOffset="20-29" id="DDI-PubMed.18443793.s8.e0" text="docetaxel" /><entity charOffset="123-132" id="DDI-PubMed.18443793.s8.e1" text="ispinesib" /><pair ddi="false" e1="DDI-PubMed.18443793.s8.e0" e2="DDI-PubMed.18443793.s8.e0" /><pair ddi="false" e1="DDI-PubMed.18443793.s8.e0" e2="DDI-PubMed.18443793.s8.e1" /></sentence><sentence text=" At least 3 pts were treated at each dose level" /><sentence text=" Limited PK samples were obtained" /><sentence text=" ANC were measured weekly on days 1, 8, 15, and 22" /><sentence text=" More ANC samples were taken from some subjects" /><sentence text=" The PK properties of ispinesib and docetaxel, and the relationship of PK with ANC were investigated using nonlinear mixed-effects models and Bayesian methods"><entity charOffset="22-31" id="DDI-PubMed.18443793.s13.e0" text="ispinesib" /><entity charOffset="36-45" id="DDI-PubMed.18443793.s13.e1" text="docetaxel" /><pair ddi="false" e1="DDI-PubMed.18443793.s13.e0" e2="DDI-PubMed.18443793.s13.e0" /><pair ddi="false" e1="DDI-PubMed.18443793.s13.e0" e2="DDI-PubMed.18443793.s13.e1" /></sentence><sentence text=" With a limited dataset, informative prior distributions for the model parameters were needed" /><sentence text=" These prior distributions were formed using information from a previous study for ispinesib, and from the literature for docetaxel"><entity charOffset="122-131" id="DDI-PubMed.18443793.s15.e0" text="docetaxel" /></sentence><sentence text="" /><sentence text="Twenty-four pts were treated in this study" /><sentence text=" The PK of ispinesib and docetaxel were well characterized by a two-compartment model and a three-compartment model, respectively"><entity charOffset="11-20" id="DDI-PubMed.18443793.s18.e0" text="ispinesib" /><entity charOffset="25-34" id="DDI-PubMed.18443793.s18.e1" text="docetaxel" /><pair ddi="false" e1="DDI-PubMed.18443793.s18.e0" e2="DDI-PubMed.18443793.s18.e0" /><pair ddi="false" e1="DDI-PubMed.18443793.s18.e0" e2="DDI-PubMed.18443793.s18.e1" /></sentence><sentence text=" There is no obvious PK interaction between ispinesib and docetaxel"><entity charOffset="58-67" id="DDI-PubMed.18443793.s19.e0" text="docetaxel" /></sentence><sentence text=" The model for ANC consisted of a proliferating compartment, three transit compartments that represented maturation, and a compartment of circulating blood cells" /><sentence text=" This ANC model has been used previously for ispinesib given as monotherapy, and for other chemotherapeutic drugs in the literature" /><sentence text=" Using Bayesian methods, the model was successfully fit for the PK of both compounds and the PD simultaneously" /><sentence text="" /><sentence text="The PK/PD model developed for ispinesib/docetaxel, may be used to examine different schedules, doses, and infusion times of both agents"><entity charOffset="40-49" id="DDI-PubMed.18443793.s24.e0" text="docetaxel" /></sentence><sentence text=" Bayesian methods allow for the use of prior information available for the model parameters" /><sentence text="" /></document>